Skip to Main Content
Page banner

TRIPATOGEN Multiplex qRT-PCR in vitro Assay for Covid19 | Influenza A+B

- INFLUENZA AND COVID19 COLIDE IN in 21./22 Season

- TWO VIRUSES, SIMILAR SYMPTOMS. COVID19 LATER.

- HIGHLY CONTAGIOUS. COVID19 SPREADS FASTER, IS LONGER CONTAGIOUS.
- BOTH CAUSE RESPIRATORY ILLNESS. COVID19 IS MORE DANGEROUS

- FLU HAS A VACCINE. COVID19 NEEDS VACCINE, PREVENTION & TESTING
- DIAGNOSTIC TEST IS NECESSARY FOR BOTH AND AT THE SAME TIME
- TRIPATOGEN  IS ONETESTWO. BETTER, FASTER, CONVENIENT.

Have you validated this method, if so, how and what were the results of the validation?

Main Advantages
1) ONE SAMPLE TESTS BOTH, INFLUENZAA+B AND COVID19.
2) LESS TIME AND RESOURCES FOR BOTH THE LAB AND THE USER.
3) IT LEADS TO BETTER AND MORE ACCURATE DIAGNOSTICS.

Is the method already deployed in a UK hospital or clinical setting?

Not yet.

Where is the kit manufactured?

Turkey.

What is the turn around time (sample-to-result) for this method?

50 Minutes

How will your solution communicate directly with the Laboratory Information Management System (LIMS)?

The test is In-Lab

How quickly could this be deployed and what are the dependencies?

Deployment in 2 weeks. Capacity 4 Million Tests per Day. No internal dependencies for delivering if administrative and commercial conditions are met.

What is the likely production volume?

Up to 6 million Kits per day. 2-3 days to double production in existing lines. 3-4 weeks to threefold production by adding new lines.

What are the risks and barriers to using this at scale?

Product quality, and Good Manufacturing Practices comply either way and capacity complies with ISO:9001 TQMS and ISO:13485 Medical Devices. 

Who are you already partnering with on this?

I am a manufacturer. 

Tagged users
You will need to login to post a comment
No comments yet, be the first to post one!
Share